Skip to main content

Advertisement

SpringerLink
Log in

Drug Targeting to the Brain

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

The goal of brain drug targeting technology is the delivery of therapeutics across the blood–brain barrier (BBB), including the human BBB. This is accomplished by re-engineering pharmaceuticals to cross the BBB via specific endogenous transporters localized within the brain capillary endothelium. Certain endogenous peptides, such as insulin or transferrin, undergo receptor-mediated transport (RMT) across the BBB in vivo. In addition, peptidomimetic monoclonal antibodies (MAb) may also cross the BBB via RMT on the endogenous transporters. The MAb may be used as a molecular Trojan horse to ferry across the BBB large molecule pharmaceuticals, including recombinant proteins, antibodies, RNA interference drugs, or non-viral gene medicines. Fusion proteins of the molecular Trojan horse and either neurotrophins or single chain Fv antibodies have been genetically engineered. The fusion proteins retain bi-functional properties, and both bind the BBB receptor, to trigger transport into brain, and bind the cognate receptor inside brain to induce the pharmacologic effect. Trojan horse liposome technology enables the brain targeting of non-viral plasmid DNA. Molecular Trojan horses may be formulated with fusion protein technology, avidin–biotin technology, or Trojan horse liposomes to target to brain virtually any large molecule pharmaceutical.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. W. M. Pardridge. Biochemistry of the human blood–brain barrier. Blood–brain barrier: interface between internal medicine and the brain. Ann. Intern. Med. 105:82–95 (1986).

    PubMed  CAS  Google Scholar 

  2. A. K. Ghose, V. N. Viswanadhan, and J. J. Wendoloski. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Com. Chem. 1:55–68 (1999).

    Article  CAS  Google Scholar 

  3. C. A. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 44:235–249 (2000).

    Article  PubMed  CAS  Google Scholar 

  4. N. H. Greig, E. M. Daly, D. J. Sweeney, and S. I. Rapoport. Pharmacokinetics of chlorambucil–tertiary butyl ester, a lipophilic chlorambucil derivative that achieves and maintains high concentrations in brain. Cancer Chemother. Pharmacol. 25:320–325 (1990).

    Article  PubMed  CAS  Google Scholar 

  5. W. M. Pardridge. Brain Drug Targeting: The Future of Brain Drug Development. Cambridge University Press, Cambridge, UK, 2001.

    Google Scholar 

  6. H. Fischer, R. Gottschlich, and A. Seelig. Blood–brain barrier permeation: molecular parameters governing passive diffusion. J. Membr. Biol. 165: 201–211 (1998).

    Article  PubMed  CAS  Google Scholar 

  7. D. J. Hingson and J. M. Diamond. Comparison of nonelectrolyte permeability patterns in several epithelia. J. Membr. Biol. 10:93–135 (1972).

    Article  PubMed  CAS  Google Scholar 

  8. B. E. Cohen and A. D. Bangham. Diffusion of small non-electrolytes across liposome membranes. Nature. 236:173–174 (1972).

    Article  PubMed  CAS  Google Scholar 

  9. W. R. Lieb and W. D. Stein. Non-Stokesian nature of transverse diffusion within human red cell membranes. J. Membr. Biol. 92:111–119 (1986).

    Google Scholar 

  10. R. J. Boado, J. Y. Li, C. Chu, F. Ogoshi, P. Wise, and W. M. Pardridge. Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1. Biochim. Biophys. Acta 1715:104–110 (2005).

    Article  PubMed  CAS  Google Scholar 

  11. Y. Kanai, H. Segawa, K. Miyamoto, H. Uchino, E. Takeda, and H. Endou. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J. Biol. Chem. 273:23629–23632 (1998).

    Article  PubMed  CAS  Google Scholar 

  12. R. Pfeiffer, B. Spindler, J. Loffing, P. J. Skelly, C. B. Shoemaker, and F. Verrey. Functional heterodimeric amino acid transporters lacking cysteine residues involved in disulfide bond. FEBS Lett. 439:157–162 (1998).

    Article  PubMed  CAS  Google Scholar 

  13. R. J. Boado, J. Y. Li, and W. M. Pardridge. Site-directed mutagenesis of rabbit LAT1 at amino acids 219 and 234. J. Neurochem. 84:1322–1331 (2003).

    Article  PubMed  CAS  Google Scholar 

  14. R. G. Blasberg, C. Patlak, and J. D. Fenstermacher. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J. Pharmacol. Exp. Ther. 195:73–83 (1975).

    PubMed  CAS  Google Scholar 

  15. N. P. Christy and R. A. Fishman. Studies of the blood–cerebrospinal fluid barrier to cortisol in the dog. J. Clin. Invest. 40:1997–2006 (1961).

    PubMed  CAS  Google Scholar 

  16. R. B. Aird. A study of intrathecal, cerebrospinal fluid-to-brain exchange. Exp. Neurol. 86:342–358 (1984).

    Article  PubMed  CAS  Google Scholar 

  17. L. K. Fung, M. Shin, B. Tyler, H. Brem, and W. M. Saltzman. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain. Pharm. Res. 13:671–682 (1996).

    Article  PubMed  CAS  Google Scholar 

  18. C. E. Krewson, M. L. Klarman, and W. M. Saltzman. Distribution of nerve growth factor following direct delivery to brain interstitium. Brain. Res. 680:196–206 (1995).

    Article  PubMed  CAS  Google Scholar 

  19. M. L. Rennels, T. F. Gregory, O. R. Blaumanis, K. Fujimoto, and P. A. Grady. Evidence for a ‘paravascular’ fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res. 326:47–63 (1985).

    Article  PubMed  CAS  Google Scholar 

  20. M. T. Krauze, R. Saito, C. Noble, J. Bringas, J. Forsayeth, T. R. McKnight, J. Park, and K. S. Bankiewicz. Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen. Exp. Neurol. 196:104–111 (2005).

    Article  PubMed  CAS  Google Scholar 

  21. I. Szentistvanyi, C. S. Patlak, R. A. Ellis, and H. F. Cserr. Drainage of interstitial fluid from different regions of rat brain. Am. J. Physiol. 246:F835–844 (1984).

    PubMed  CAS  Google Scholar 

  22. H. Davson, K. Welch, and M.B. Segal. Secretion of cerebrospinal fluid. In The Physiology and Pathophysiology of the Cerebrospinal Fluid. Churchill Livingstone, London, 1987, p. 201.

  23. Y. Ai, W. Markesbery, Z. Zhang, R. Grondin, D. Elseberry, G. A. Gerhardt, and D. M. Gash. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J. Comp. Neurol. 461:250–261 (2003).

    Article  PubMed  CAS  Google Scholar 

  24. T. C. Anand Kumar, G. F. David, A. Sankaranarayanan, V. Puri, and K. R. Sundram. Pharmacokinetics of progesterone after its administration to ovariectomized rhesus monkeys by injection, infusion, or nasal spraying. Proc. Natl. Acad. Sci. U. S. A. 79:4185–4189 (1982).

    Article  PubMed  CAS  Google Scholar 

  25. T. Sakane, M. Akizuki, S. Yamashita, T. Nadai, M. Hashida, and H. Sezaki. The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem. Pharm. Bull. (Tokyo). 39:2456–2458 (1991).

    CAS  Google Scholar 

  26. H. Yamazumi. Infiltration of India ink from subarachnoid space to nasal mucosa along olfactory nerves in rabbits. Nippon Jibi Inkoka Gakkai Kaiho. 92:608–616 (1989).

    CAS  Google Scholar 

  27. P. Merkus, H. J. Guchelaar, D. A. Bosch, and F. W. Merkus. Direct access of drugs to the human brain after intranasal drug administration? Neurology. 60:1669–1671 (2003).

    PubMed  CAS  Google Scholar 

  28. W. M. Pardridge. Blood–brain barrier delivery. Drug Discov Today. 12:54–61 (2007).

    Article  PubMed  CAS  Google Scholar 

  29. M. P. van den Berg, P. Merkus, S. G. Romeijn, J. C. Verhoef, and F. W. Merkus. Uptake of melatonin into the cerebrospinal fluid after nasal and intravenous delivery: studies in rats and comparison with a human study. Pharm. Res. 21:799–802 (2004).

    Article  PubMed  Google Scholar 

  30. W. H. Oldendorf. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am. J. Physiol. 221:1629–1639 (1971).

    PubMed  CAS  Google Scholar 

  31. W. M. Pardridge. Brain metabolism: a perspective from the blood–brain barrier. Physiol. Rev. 63:1481–1535 (1983).

    PubMed  CAS  Google Scholar 

  32. W. M. Pardridge, R. J. Boado, and C. R. Farrell. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood–brain barrier. Studies with quantitative western blotting and in situ hybridization. J. Biol. Chem. 265:18035–18040 (1990).

    PubMed  CAS  Google Scholar 

  33. J. Y. Li, R. J. Boado, and W. M. Pardridge. Cloned blood–brain barrier adenosine transporter is identical to the rat concentrative Na+ nucleoside cotransporter CNT2. J. Cereb. Blood Flow Metab. 21:929–936 (2001).

    Article  PubMed  CAS  Google Scholar 

  34. W. M. Pardridge, T. Yoshikawa, Y. S. Kang, and L. P. Miller. Blood–brain barrier transport and brain metabolism of adenosine and adenosine analogs. J. Pharmacol. Exp. Ther. 268:14–18 (1994).

    PubMed  CAS  Google Scholar 

  35. A. Tsuji and I. I. Tamai. Carrier-mediated or specialized transport of drugs across the blood–brain barrier. Adv. Drug. Deliv. Rev. 36:277–290 (1999).

    Article  PubMed  CAS  Google Scholar 

  36. T. Terasaki and K. Hosoya. The blood–brain barrier efflux transporters as a detoxifying system for the brain. Adv. Drug Deliv. Rev. 36:195–209 (1999).

    Article  PubMed  CAS  Google Scholar 

  37. H. Kusuhara and Y. Sugiyama. Efflux transport systems for drugs at the blood–brain barrier and blood–cerebrospinal fluid barrier (Part 1). Drug Discov. Today. 6:150–156 (2001).

    Article  PubMed  CAS  Google Scholar 

  38. T. Terasaki. Development of Brain Efflux Index (BEI) method and its application to the blood–brain barrier efflux transport study. In Introduction to the Blood–Brain Barrier; Methodology, Biology and Pathology, Cambridge University Press, Cambridge, 1998, pp. 24–31.

  39. E. M. Cornford, S. Hyman, M. E. Cornford, and M. J. Caron. Glut1 glucose transporter activity in human brain injury. J. Neurotrauma. 13:523–536 (1996).

    Article  PubMed  CAS  Google Scholar 

  40. K. R. Duffy and W. M. Pardridge. Blood–brain barrier transcytosis of insulin in developing rabbits. Brain Res. 420:32–38 (1987).

    Article  PubMed  CAS  Google Scholar 

  41. J. Holly and C. Perks. The role of insulin-like growth factor binding proteins. Neuroendocrinology. 83:154–160 (2006).

    Article  PubMed  CAS  Google Scholar 

  42. W. M. Pardridge, J. L. Buciak, and P. M. Friden. Selective transport of an anti-transferrin receptor antibody through the blood–brain barrier in vivo. J. Pharmacol. Exp. Ther. 259:66–70 (1991).

    PubMed  CAS  Google Scholar 

  43. Y. Zhang and W. M. Pardridge. Mediated efflux of IgG molecules from brain to blood across the blood–brain barrier. J. Neuroimmunol. 114:168–172 (2001).

    Article  PubMed  CAS  Google Scholar 

  44. H. F. Cserr, D. N. Cooper, P. K. Suri, and C. S. Patlak. Efflux of radiolabeled polyethylene glycols and albumin from rat brain. Am. J. Physiol. 240:F319–F328 (1981).

    PubMed  CAS  Google Scholar 

  45. F. Schlachetzki, C. Zhu, and W. M. Pardridge. Expression of the neonatal Fc receptor (FcRn) at the blood–brain barrier. J. Neurochem. 81:203–206 (2002).

    Article  PubMed  CAS  Google Scholar 

  46. D. Triguero, J. Buciak, and W. M. Pardridge. Capillary depletion method for quantification of blood–brain barrier transport of circulating peptides and plasma proteins. J. Neurochem. 54:1882–1888 (1990).

    Article  PubMed  CAS  Google Scholar 

  47. H. J. Lee, B. Engelhardt, J. Lesley, U. Bickel, and W. M. Pardridge. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood–brain barrier in mouse. J. Pharmacol. Exp. Ther. 292:1048–1052 (2000).

    PubMed  CAS  Google Scholar 

  48. W. M. Pardridge, Y. S. Kang, J. L. Buciak, and J. Yang. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood–brain barrier in vivo in the primate. Pharm. Res. 12:807–816 (1995).

    Article  PubMed  CAS  Google Scholar 

  49. D. Wu, J. Yang, and W. M. Pardridge. Drug targeting of a peptide radiopharmaceutical through the primate blood–brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Invest. 100:1804–1812 (1997).

    Article  PubMed  CAS  Google Scholar 

  50. T. S. Salahuddin, B. B. Johansson, H. Kalimo, and Y. Olsson. Structural changes in the rat brain after carotid infusions of hyperosmolar solutions. An electron microscopic study. Acta Neuropathol. (Berlin). 77:5–13 (1988).

    Article  CAS  Google Scholar 

  51. A. S. Lossinsky, A. W. Vorbrodt, and H. M. Wisniewski. Scanning and transmission electron microscopic studies of microvascular pathology in the osmotically impaired blood–brain barrier. J. Neurocytol. 24:795–806 (1995).

    Article  PubMed  CAS  Google Scholar 

  52. E. A. Neuwelt and S. I. Rapoport. Modification of the blood–brain barrier in the chemotherapy of malignant brain tumors. Fed. Proc. 43:214–219 (1984).

    PubMed  CAS  Google Scholar 

  53. L. I. Larsson, J. Fahrenkrug, O. Schaffalitzky De Muckadell, F. Sundler, R. Hakanson, and J. R. Rehfeld. Localization of vasoactive intestinal polypeptide (VIP) to central and peripheral neurons. Proc. Natl. Acad. Sci. U. S. A. 73:3197–3200 (1976).

    Article  PubMed  CAS  Google Scholar 

  54. J. McCulloch and L. Edvinsson. Cerebral circulatory and metabolic effects of vasoactive intestinal polypeptide. Am. J. Physiol. 238:H449–H456 (1980).

    PubMed  CAS  Google Scholar 

  55. D. Wu and W. M. Pardridge. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood–brain barrier drug delivery system. J. Pharmacol. Exp. Ther. 279:77–83 (1996).

    PubMed  CAS  Google Scholar 

  56. D. Wu and W. M. Pardridge. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc. Natl. Acad. Sci. U. S. A. 96:254–259 (1999).

    Article  PubMed  CAS  Google Scholar 

  57. T. Sakane and W. M. Pardridge. Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. Pharm. Res. 14:1085–1091 (1997).

    Article  PubMed  CAS  Google Scholar 

  58. Y. Zhang and W. M. Pardridge. Conjugation of brain-derived neurotrophic factor to a blood–brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res. 889:49–56 (2001).

    Article  PubMed  CAS  Google Scholar 

  59. Y. Zhang and W. M. Pardridge. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood–brain barrier drug targeting system. Stroke. 32:1378–1384 (2001).

    PubMed  CAS  Google Scholar 

  60. B. W. Song, H. V. Vinters, D. Wu, and W. M. Pardridge. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood–brain barrier delivery vector. J. Pharmacol. Exp. Ther. 301:605–610 (2002).

    Article  PubMed  CAS  Google Scholar 

  61. L. Belayev, R. Busto, W. Zhao, and M. D. Ginsberg. Quantitative evaluation of blood–brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res. 739:88–96 (1996).

    Article  PubMed  CAS  Google Scholar 

  62. A. Kurihara and W. M. Pardridge. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood–brain barrier. Cancer Res. 59:6159–6163 (1999).

    PubMed  CAS  Google Scholar 

  63. A. Kurihara, Y. Deguchi, and W. M. Pardridge. Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood–brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. Bioconjug. Chem. 10:502–511 (1999).

    Article  PubMed  CAS  Google Scholar 

  64. H. J. Lee, Y. Zhang, C. Zhu, K. Duff, and W. M. Pardridge. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J. Cereb. Blood Flow Metab. 22:223–231 (2002).

    Article  PubMed  CAS  Google Scholar 

  65. Y. Saito, J. Buciak, J. Yang, and W. M. Pardridge. Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1–40 through the blood–brain barrier and binding to Alzheimer disease amyloid of the A beta 1–40/vector complex. Proc. Natl. Acad. Sci. U. S. A. 92:10227–10231 (1995).

    Article  Google Scholar 

  66. T. Suzuki, D. Wu, F. Schlachetzki, J. Y. Li, R. J. Boado, and W. M. Pardridge. Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J. Nucl. Med. 45:1766–1775 (2004).

    PubMed  CAS  Google Scholar 

  67. T. Suzuki, Y. Zhang, Y. F. Zhang, F. Schlachetzki, and W. M. Pardridge. Imaging gene expression in regional brain ischemia in vivo with a targeted [111in]-antisense radiopharmaceutical. Mol. Imaging 3:356–363 (2004).

    Article  PubMed  CAS  Google Scholar 

  68. W. M. Pardridge, R. J. Boado, and Y. S. Kang. Vector-mediated delivery of a polyamide (“peptide”) nucleic acid analogue through the blood–brain barrier in vivo. Proc. Natl. Acad. Sci. U. S. A. 92:5592–5596 (1995).

    Article  PubMed  CAS  Google Scholar 

  69. Y. Zhang and W. M. Pardridge. Delivery of beta-galactosidase to mouse brain via the blood–brain barrier transferrin receptor. J. Pharmacol. Exp. Ther. 313:1075–1081 (2005).

    Article  PubMed  CAS  Google Scholar 

  70. M. J. Coloma, H. J. Lee, A. Kurihara, E. M. Landaw, R. J. Boado, S. L. Morrison, and W. M. Pardridge. Transport across the primate blood–brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm. Res. 17:266–274 (2000).

    Article  PubMed  CAS  Google Scholar 

  71. R. J. Boado, Y. Zhang, and W. M. Pardridge. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood–brain barrier. Biotechnol. Bioeng. 96:381–391 (2007).

    Article  PubMed  CAS  Google Scholar 

  72. R. J. Boado, Y. Zhang, and W. M. Pardridge. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood–brain barrier. Biotechnol. Bioeng. in press (2007).

  73. R. J. Boado, Y. Zhang, C. F. Xia, and W. M. Pardridge. Fusion antibody for Alzheimer’s disease with bidirectional transport across the blood–brain barrier and abeta fibril disaggregation. Bioconjug Chem. 18:447–455 (2007).

    Google Scholar 

  74. J. Norman, W. Denham, D. Denham, J. Yang, G. Carter, A. Abouhamze, C. L. Tannahill, S. L. MacKay, and L. L. Moldawer. Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation. Gene Ther. 7:1425–1430 (2000).

    Article  PubMed  CAS  Google Scholar 

  75. D. Simberg, S. Weisman, Y. Talmon, A. Faerman, T. Shoshani, and Y. Barenholz. The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection. J. Biol. Chem. 278:39858–39865 (2003).

    Article  PubMed  CAS  Google Scholar 

  76. N. Shi and W. M. Pardridge. Noninvasive gene targeting to the brain. Proc. Natl. Acad. Sci. U. S. A. 97:7567–7572 (2000).

    Article  PubMed  CAS  Google Scholar 

  77. Y. Zhang, F. Schlachetzki, and W. M. Pardridge. Global non-viral gene transfer to the primate brain following intravenous administration. Mol. Ther. 7:11–18 (2003).

    Article  PubMed  CAS  Google Scholar 

  78. N. Shi, Y. Zhang, C. Zhu, R. J. Boado, and W. M. Pardridge. Brain-specific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. U. S. A. 98:12754–12759 (2001).

    Article  PubMed  CAS  Google Scholar 

  79. N. Shi, R. J. Boado, and W. M. Pardridge. Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm. Res. 18:1091–1095 (2001).

    Article  PubMed  CAS  Google Scholar 

  80. Y. Zhang, F. Schlachetzki, J. Y. Li, R. J. Boado, and W. M. Pardridge. Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. Mol. Vis. 9:465–472 (2003).

    PubMed  CAS  Google Scholar 

  81. D. J. Zack, J. Bennett, Y. Wang, C. Davenport, B. Klaunberg, J. Gearhart, and J. Nathans. Unusual topography of bovine rhodopsin promoter-lacZ fusion gene expression in transgenic mouse retinas. Neuron. 6:187–199 (1991).

    Article  PubMed  CAS  Google Scholar 

  82. C. Zhu, Y. Zhang, Y. F. Zhang, J. Yi Li, R. J. Boado, and W. M. Pardridge. Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice. J. Gene Med. 6:906–912 (2004).

    Article  PubMed  CAS  Google Scholar 

  83. Y. Zhang, F. Schlachetzki, Y. F. Zhang, R. J. Boado, and W. M. Pardridge. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum. Gene Ther. 15:339–350 (2004).

    Article  PubMed  CAS  Google Scholar 

  84. Y. Zhang, C. Zhu, and W. M. Pardridge. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol. Ther. 6:67–72 (2002).

    Article  PubMed  CAS  Google Scholar 

  85. Y. Zhang, Y. F. Zhang, J. Bryant, A. Charles, R. J. Boado, and W. M. Pardridge. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 10:3667–3677 (2004).

    Article  PubMed  CAS  Google Scholar 

  86. W. M. Pardridge. Recent advances in blood–brain barrier transport. Annu. Rev. Pharmacol. Toxicol. 28:25–39 (1988).

    Article  PubMed  CAS  Google Scholar 

  87. Y. F. Zhang, R. J. Boado, and W. M. Pardridge. Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm. Res. 20:1779–1785 (2003).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, UCLA, Warren Hall 13-164 900 Veteran Ave, Los Angeles, CA, 90024, USA

    William M. Pardridge

Authors
  1. William M. Pardridge
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William M. Pardridge.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pardridge, W.M. Drug Targeting to the Brain. Pharm Res 24, 1733–1744 (2007). https://doi.org/10.1007/s11095-007-9324-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-007-9324-2

Key words

Search

Navigation